Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...